Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Recruitment status was: Active, not recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls|
- Knee cartilage volume [ Time Frame: Two years ]
- Menopausal symptoms [ Time Frame: Two years ]
- Well-being [ Time Frame: Two years ]
|Study Start Date:||May 2005|
|Estimated Study Completion Date:||December 2010|
|Estimated Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
The mechanism of increased bone loss and fracture risk is clearly related to the depletion of estrogen production in the bone. But why there is a higher rate of reporting arthralgia, fracture and joint pain amongst women on aromatase inhibitors is not understood.
Using magnetic resonance imaging (MRI) to measure knee articular cartilage volume, we have demonstrated that post menopausal hormone therapy used for at least five years is associated with retention of articular cartilage in the knee, indicating that oestrogen may protect against the development of osteoarthritis in post menopausal women. Furthermore, we have recently observed that free testosterone is associated with loss of tibial cartilage, after taking into account age, body mass index, baseline tibial cartilage volume, tibial plateau area and total bone mineral content in healthy men. Whether an excess of testosterone to oestrogen as a consequence of aromatase inhibition has an adverse effect on articular cartilage volume warrants further investigation.
This study will include non-hysterectomised women aged 40 to 65 years who have undergone breast surgery and then commenced on aromatase inhibitors within the preceding 12 weeks. The control group (which has been fully recruited) included non-hysterectomised, healthy women aged 40 to 65 years. A MRI of the dominant knee will be used to compare changes in knee articular volume over time. A MRI will be done at baseline and again at 2 years. Changes in knee articular volume is the primary outcome. We will also use this opportunity to compare menopausal symptoms (assessed using the Menopause Quality of Life [MENQOL] questionnaire) between women treated with aromatase inhibitors and those who are not. Well-being will also be assessed using the Psychological General Well-Being index.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00111241
|Women's Health Program, Monash University|
|Melbourne, Victoria, Australia, 3181|
|Principal Investigator:||Susan Davis, MBBS FRACP PhD||Director Women's Health Program|